What Is Fecal Lactoferrin and What Does It Indicate?

Fecal lactoferrin is a protein found in stool that serves as a marker of intestinal inflammation. When your gut lining is inflamed, white blood cells called neutrophils flood into the tissue, and lactoferrin spills from those cells into the intestinal space, eventually appearing in your stool at measurable levels. Clinicians order the test primarily to help distinguish inflammatory bowel disease from irritable bowel syndrome and to track how active gut inflammation is over time. The test is simple, requiring only a stool sample, and it has become one of the more reliable noninvasive tools for evaluating what is happening inside the intestines without a colonoscopy.

Why Lactoferrin Ends Up in Your Stool

Lactoferrin is an iron-binding protein that exists throughout the body. It shows up in breast milk, tears, saliva, and nasal secretions. But the lactoferrin that matters for this test comes from a specific source: neutrophils, the most abundant type of white blood cell in your immune system. Neutrophils carry lactoferrin in their internal storage compartments and release it when they arrive at a site of infection or inflammation. In a healthy gut, very little lactoferrin makes it into the stool. When the intestinal lining is inflamed, though, neutrophils rush in and release their contents, causing lactoferrin levels in stool to spike dramatically.

Beyond simply being a marker, lactoferrin has its own biological job. Its ability to bind iron starves certain bacteria of a nutrient they need to grow. It can also latch onto bacterial cell walls directly, disrupting the membrane and killing the organism. This is especially effective against certain types of bacteria, including some that cause gut infections.¹ So lactoferrin is both a signal that inflammation is present and a weapon the body uses to fight off invaders.

Separating Inflammatory Bowel Disease from Irritable Bowel Syndrome

This is the test’s single most common clinical role. Inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) can produce overlapping symptoms: cramping, diarrhea, bloating, urgency. But they are fundamentally different conditions. IBD involves visible damage and inflammation in the gut wall, while IBS is a functional disorder with no structural damage. Telling them apart matters enormously because the treatments, the monitoring, and the long-term risks are completely different.

A meta-analysis pooling data from multiple studies found that fecal lactoferrin correctly identified about 78% of IBD cases (pooled sensitivity) while correctly ruling out IBD in about 94% of non-IBD patients (pooled specificity). The overall diagnostic accuracy was high, with the test performing well enough to meaningfully separate the two conditions.² A more recent study from a Bangladeshi cohort found even stronger numbers at a specific cutoff value: 88% sensitivity and 84% specificity, with a positive predictive value of 92%.³

What does that mean in practical terms? If your fecal lactoferrin comes back negative, there is a strong chance that your symptoms are not being caused by IBD. That negative result can spare you from an unnecessary colonoscopy, which is invasive, expensive, and requires bowel preparation that most people would prefer to avoid. A positive result, on the other hand, does not confirm IBD by itself, but it raises a clear flag that endoscopic evaluation is warranted.

Tracking Gut Inflammation in People with Known IBD

Once someone has been diagnosed with IBD, the question shifts from “do I have it?” to “how active is it right now?” This is trickier than it sounds. Symptoms alone are unreliable indicators of what is happening at the tissue level. A person can feel relatively well while mucosal inflammation quietly persists, or can have discomfort driven by factors other than active disease. Endoscopy is the gold standard for assessing mucosal inflammation, but performing one every few months is impractical.

Fecal lactoferrin fills this gap reasonably well. Studies in both Crohn’s disease and ulcerative colitis have found that lactoferrin levels correlate with endoscopic inflammation scores. One study found a strong correlation between fecal lactoferrin and the endoscopic severity index in Crohn’s disease, and that lactoferrin outperformed common blood markers like CRP in reflecting what was actually happening on the intestinal surface.⁴ Another study confirmed that both fecal lactoferrin and CRP showed the strongest correlations with endoscopic disease scores across IBD patients generally.⁵

This advantage over blood tests makes intuitive sense. CRP is a systemic marker. It rises in response to inflammation anywhere in the body, whether from a joint, a wound, or the intestines. Fecal lactoferrin, by contrast, is produced locally in the gut. A comparison of multiple stool markers against CRP found that all three stool markers were superior to CRP in their ability to reflect endoscopic inflammation.⁶ If your doctor wants to know whether your IBD is flaring in the gut specifically, a stool test gives a more focused answer than a blood draw.

Monitoring Whether a Biologic Drug Is Working

For people with moderate to severe IBD, biologic therapies are often the backbone of treatment. Knowing early whether a drug is working can prevent months of futile treatment and lingering inflammation. Fecal lactoferrin has shown promise here as well.

In one study of Crohn’s disease patients starting anti-TNF therapy, lactoferrin levels dropped sharply alongside endoscopic improvement. In patients who achieved endoscopic remission, median fecal lactoferrin fell from roughly 92 µg/g before treatment to under 2 µg/g afterward.⁷ That kind of dramatic decline mirrors what the endoscope shows, and it can be tracked with a simple stool sample rather than repeated colonoscopies.

Research has also explored whether early lactoferrin trends can predict who will respond to biologic therapy and who will not. One study found that patients who responded to treatment showed lactoferrin values that continued to drop after each infusion, while nonresponders saw an initial dip followed by a rebound. Patterns in the first couple of measurements were able to accurately predict the treatment outcome at the end of the induction period.⁸ If this approach becomes standard, it could allow doctors to switch medications sooner in patients who are unlikely to benefit, sparing them weeks or months on a drug that is not working.

Predicting Flares Before They Happen

One of the more useful applications of fecal lactoferrin is catching a relapse before symptoms fully develop. IBD flares tend to build gradually at the tissue level before a patient notices worsening symptoms. A rising lactoferrin level in someone who feels fine may be an early warning signal.

A study tracking IBD patients in remission found that those who tested positive for fecal lactoferrin had a significantly higher relapse rate than those who tested negative (roughly 25% versus 10%). Both lactoferrin positivity and elevated fecal calprotectin were independently associated with relapse risk in multivariate analysis.⁹ This makes serial testing, checking the marker at regular intervals even when a patient feels well, potentially valuable for catching trouble early and adjusting treatment preemptively.

What Fecal Lactoferrin Tells You About Infectious Diarrhea

The test is not limited to IBD. Because lactoferrin rises whenever neutrophils pour into the gut lining, it also goes up during bacterial gastroenteritis. This has a practical application: when someone shows up with acute diarrhea, the cause is often unclear. Is it bacterial, requiring antibiotics, or viral, requiring only supportive care?

Fecal lactoferrin levels tend to be substantially higher in bacterial infections than in viral ones. One study found that patients with Salmonella or Campylobacter infections had mean fecal lactoferrin levels several times higher than those with rotavirus or norovirus.¹⁰ This makes sense biologically. Invasive bacteria damage the gut wall and trigger a massive neutrophil response, while most viral infections cause diarrhea through different mechanisms with less direct tissue invasion.

A systematic review and meta-analysis confirmed that fecal lactoferrin showed fair accuracy in distinguishing acute gastroenteritis caused by invasive bacteria from cases with negative cultures, suggesting it could serve as a useful screening tool.¹¹ Another study found that patients who tested positive for fecal lactoferrin during acute diarrhea were more likely to have moderate-to-severe dehydration and more likely to have a bacterial pathogen identified on testing.¹² In practice, a positive lactoferrin in the context of acute diarrhea signals that the illness may be more serious and that bacterial workup is worth pursuing.

How the Test Performs in Children

Diagnosing IBD in children carries its own challenges. Kids are harder to put through invasive testing, and symptoms in younger patients can be vague or attributed to other causes. Fecal lactoferrin has been studied specifically in pediatric populations and performs well.

A study of children and young adults with IBD found that lactoferrin levels were dramatically higher in those with ulcerative colitis or Crohn’s disease compared to healthy controls under 21. The difference was not subtle: IBD patients had levels roughly a thousandfold higher than healthy young people.¹³ Another pediatric study found that an elevated lactoferrin cutoff precisely separated children with intestinal inflammation from those with normal intestinal lining, and that children with normal lactoferrin levels had no evidence of microscopic or tissue-level inflammation.¹⁴ For parents and pediatricians trying to decide whether a child’s persistent stomach symptoms warrant endoscopy, a fecal lactoferrin test can provide useful guidance without any needles or sedation.

Fecal Lactoferrin vs. Fecal Calprotectin

The other major stool inflammation marker is fecal calprotectin, and it gets far more attention in clinical guidelines. Both proteins come from neutrophils, both rise with gut inflammation, and both are measured from a simple stool sample. So why does calprotectin tend to dominate the conversation?

Part of the answer is momentum. Calprotectin was commercialized earlier and has been more widely studied. It also has a practical edge in stability: calprotectin is extremely resistant to breakdown and can sit at room temperature for days without degrading, which makes shipping and handling samples easier. Lactoferrin is also relatively stable in stool, but calprotectin’s reputation for hardiness gave it a head start in widespread adoption.

In terms of actual diagnostic performance, the two are close. A study comparing both markers for evaluating IBD activity found that fecal calprotectin and lactoferrin had nearly equivalent abilities in detecting clinical remission in ulcerative colitis, though calprotectin was slightly superior overall.¹⁵ Meanwhile, a meta-analysis of fecal lactoferrin for IBD diagnosis found pooled sensitivity of 82% and specificity of 95%, numbers that are competitive with most published calprotectin data.¹⁶ In practice, whether your doctor orders one or the other often depends more on what the local lab offers than on a meaningful clinical difference between the two.

Where the Test Falls Short

Fecal lactoferrin is a marker of neutrophilic inflammation in the gut, and that is both its strength and its limitation. Any condition that sends neutrophils into the intestinal lining will raise lactoferrin, not just IBD. Bacterial infections, as discussed above, will do it. So will other inflammatory conditions such as celiac disease when it is active, certain medication-induced injuries to the gut, and some colorectal tumors. The test tells you inflammation is present; it does not tell you the cause.

There is also an asymmetry in how well the test detects Crohn’s disease versus ulcerative colitis. The same meta-analysis that found strong overall numbers reported that sensitivity for Crohn’s disease (about 75%) was noticeably lower than for ulcerative colitis (about 82%), even though specificity was excellent for both.¹⁶ This likely reflects the patchy, transmural nature of Crohn’s inflammation, which may not always generate as robust a neutrophil presence in the intestinal lumen as the continuous mucosal inflammation typical of ulcerative colitis. A negative lactoferrin in someone with suspected Crohn’s disease should be interpreted with more caution than the same result in someone suspected of having ulcerative colitis.

Medications can also complicate interpretation. Nonsteroidal anti-inflammatory drugs (NSAIDs) are known to cause small-bowel injury and can raise fecal inflammation markers. If you are taking regular NSAIDs and your lactoferrin comes back elevated, the result may reflect drug-induced mucosal damage rather than IBD or infection. Your doctor should consider your medication list when interpreting any stool inflammation test.

Practical Considerations for Getting Tested

From a patient’s perspective, the test itself is straightforward. You collect a small stool sample at home using a kit provided by your lab. No fasting or bowel preparation is needed. The sample is sent to the lab, and results typically come back within a few days. Some clinics now offer point-of-care rapid tests that give a qualitative positive or negative result in minutes, though these sacrifice the quantitative precision of a full lab assay.

One of the practical benefits of fecal lactoferrin testing is its role in reducing unnecessary endoscopies. Colonoscopy is safe and effective but carries costs, requires time off work, demands uncomfortable preparation, and in rare cases can cause complications. By using a stool marker to screen patients with gastrointestinal symptoms, clinicians can prioritize endoscopy for those most likely to have genuine inflammatory disease and reassure those with negative markers that watchful waiting or IBS-directed treatment is reasonable.

If you have already been diagnosed with IBD, serial lactoferrin measurements can serve as a kind of ongoing inflammation check-in between endoscopies. A stable, low level provides reassurance. A rising trend, even when you feel fine, might prompt your gastroenterologist to adjust your therapy before a full flare develops. The test is not a replacement for endoscopy when important decisions hinge on the result, but it fills a valuable space between doing nothing and scoping every time a question arises.

Why Stool Markers Are Not Interchangeable with Blood Tests

It is worth understanding why your doctor might order a stool test when a blood draw seems simpler. The most commonly used blood marker for inflammation in gastroenterology is CRP. It is easy to obtain and widely available, but it reflects inflammation everywhere in the body, not just the gut. Someone with a bad knee, an upper respiratory infection, or even significant obesity can have an elevated CRP that has nothing to do with their intestines. Conversely, someone with mild but real intestinal inflammation can have a perfectly normal CRP.

Stool markers like lactoferrin bypass this problem by measuring inflammation at its source. The protein shows up in the stool because it was released in the gut, so it provides a more direct read on intestinal health. Studies have consistently found that stool markers outperform CRP in their ability to reflect endoscopic findings.⁶ This does not mean CRP is useless in IBD management; it still adds value in some contexts, especially when combined with clinical symptoms and stool markers. But if you have to pick one test to gauge what is happening in the gut, a stool marker wins.